A Pipeline Built With Purpose

Leading with science and compassion, our team purposefully builds our pipeline to improve patients’ lives, relentlessly pushing science forward by creatively investigating pathways to reveal uncharted scientific discoveries and deliver transformational medicines.

Program
Potential Indication
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

UPLIZNA® (inebilizumab-cdon)

IgG4-Related Disease

Phase 3

Myasthenia Gravis

Phase 3

A humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody (mAb) that binds to the B cell-specific surface antigen CD19.

IgG4-Related Disease: Phase 3 trial evaluating UPLIZNA for the prevention of flare in patients with IgG4-related disease.

MINT: Phase 3 trial evaluating UPLIZNA for improving outcomes in patients with myasthenia gravis.

HZN-825

Diffuse Cutaneous Systemic Sclerosis

Phase 2

Idiopathic Pulmonary Fibrosis

Phase 2

A molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). We are initiating a Phase 2b pivotal trial in diffuse cutaneous systemic sclerosis and a Phase 2b pivotal trial in idiopathic pulmonary fibrosis.

Learn more about the HZN-825 trial in idiopathic pulmonary fibrosis here.

Dazodalibep (HZN-4920)

Focal Segmental Glomerulosclerosis

Phase 2

Kidney Transplant Rejection

Phase 2

Rheumatoid Arthritis

Phase 2

Sjögren’s Syndrome

Phase 2

A fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. We are investigating dazodalibep in focal segmental glomerulosclerosis as well as conducting Phase 2 trials in kidney transplant rejection, rheumatoid arthritis and Sjögren’s syndrome.

Daxdilimab (HZN-7734)

Alopecia Areata

Phase 2

Dermatomyositis

Phase 2

Discoid Lupus Erythematosus

Phase 2

Lupus Nephritis

Phase 2

Systemic Lupus Erythematosus

Phase 2

A fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus erythematosus.

TEPEZZA® (teprotumumab-trbw)

TED in Japan (OPTIC-J)

Phase 3

Diffuse Cutaneous Systemic Sclerosis

Phase 1

Subcutaneous Administration

Phase 1

A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R).

TED in Japan (OPTIC-J): Phase 3 randomized, placebo-controlled trial in Japan initiated to evaluate TEPEZZA in patients with moderate-to-severe active TED.

Diffuse Cutaneous Systemic Sclerosis: Phase 1 trial exploring TEPEZZA in diffuse cutaneous systemic sclerosis.

Subcutaneous Administration: Phase 1 pharmacokinetic trial to explore subcutaneous administration of TEPEZZA.

HZN-1116

Autoimmune Diseases

Phase 1

A fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. We are conducting a Phase 1 trial in autoimmune diseases.

Alpine 

Autoimmune Diseases

Pre-clinical

Exclusive collaboration to develop novel, multi-specific fusion protein based therapies for autoimmune and inflammatory diseases.

Arrowhead

Next-Gen Uncontrolled Gout

Pre-clinical

Exclusive collaboration to investigate a short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase in the liver (GalNAc) to reduce serum uric acid and treat uncontrolled gout.

HemoShear

Novel Gout Targets

Pre-clinical

Exclusive collaboration to discover new therapeutics for novel gout targets by combining HemoShear’s discovery expertise with Horizon’s rheumatology development and commercialization expertise.


BRAND NAME (generic name)
Lorem ipsum dolor sit amet

BRAND NAME (generic name)
Lorem ipsum dolor sit amet

Moving On-Market Medicines Forward

Horizon is exploring the potential of its on-market medicines to identify paths for new treatment methods and improve patient outcomes.

A recombinant uricase enzyme that breaks down uric acid.

AGILE: Phase 4 trial evaluating the impact of administering KRYSTEXXA over a shorter infusion duration in patients with uncontrolled gout who are receiving methotrexate.

FORWARD OL: Phase 4 trial evaluating monthly dosing of KRYSTEXXA with methotrexate in patients with uncontrolled gout.

Retreatment: Phase 4 trial evaluating KRYSTEXXA with methotrexate in patients who have previously failed KRYSTEXXA monotherapy.

A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R).

Chronic Thyroid Eye Disease (TED): Phase 4 trial evaluating TEPEZZA in chronic TED to generate additional clinical data in this patient population.

Clinical Trials

Clinical trials are essential to the research and development process and play a vital role in helping physicians and investigators understand how an investigational medicine may safely and effectively treat a specific disease or condition.

For a comprehensive list of current clinical trials involving Horizon medicines, please visit: www.clinicaltrials.gov.

For more information about expanded access programs, read our Expanded Access Policy Statement.

This information was last updated on August 3, 2022.

C-HZN-00316-13